J2G-MC-JZJX: LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506784-33-00

Acronym

J2G-MC-JZJX

Enrollment

Registered

2024-05-23

Start date

2021-01-19

Completion date

Unknown

Last updated

2025-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

RET fusion-Positive NSCLC

Brief summary

EFS by investigator assessment in the primary analysis population

Interventions

DRUGSELPERCATINIB

DRUGPlacebo to match LY3527723

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
EFS by investigator assessment in the primary analysis population	—

Countries

Austria, Belgium, Czechia, Denmark, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Romania, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026